| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 11, 2007
Accepted on May 24, 2007
Department of Obstetrics and Gynaecology, QE II Building (DO2) University of Sydney, NSW, 2006, Australia, 2006; RTI International Research Triangle Park, NC 27709, Prince Henry's Institute, Monash Medical Centre, Clayton, VIC, Australia, 3168
* To whom correspondence should be addressed. E-mail: ghale{at}med.usyd.edu.au.
Context: Female reproductive aging based on changes in menstrual cycle length and frequency, progresses through a number of stages as defined by the STRAW (Stages of Reproductive Aging Workshop) staging criteria.
Objective: This paper provides a comprehensive description of the endocrine features associated with the STRAW stages.
Design: Healthy women aged 21-35 and 45-55 submitted three blood samples a week for over a single menstrual cycle. They were classified as mid-reproductive age (MRA; N=21), late reproductive age (LRA; N=16), early menopause transition (EMT; N=16) and late menopause transition (LMT; N=23).
Results: There were 9, 1, 0 and 2 anovulatory cycles identified in the LMT, EMT, LRA and MRA groups respectively. Ovulatory cycle FSH, LH and estradiol (E2) levels increased with progression of STRAW stage (P = 0.001; P < 0.01; P < 0.05 respectively), and mean luteal phase serum progesterone decreased (P < 0.01). Early cycle (ovulatory and anovulatory) inhibin B (INHB) decreased steadily across the STRAW stages (P < 0.01) and was largely undetectable during elongated ovulatory and anovulatory cycles in the menopause transition. Anti-Mullerian Hormone (AMH) decreased markedly (10-15 fold) and progressively across the STRAW stages (P < 0.01; P < 0.001 respectively).
Conclusions: Progression through the STRAW Stages is associated with elevations in serum FSH, LH, E2 and decreases in luteal phase P. The marked fall in INHB and particularly AMH indicate that they may be useful in predicting STRAW Stage but future analyses of early cycle measurements on larger cohorts are needed to draw predictive conclusions.
This article has been cited by other articles:
![]() |
J. Rohr, E.G. Allen, K. Charen, J. Giles, W. He, C. Dominguez, and S.L. Sherman Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study Hum. Reprod., May 1, 2008; 23(5): 1220 - 1225. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |